BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 29898687)

  • 21. Clinicopathologic features of 300 rhabdomyosarcomas with emphasis upon differential expression of skeletal muscle specific markers in the various subtypes: A single institutional experience.
    Rekhi B; Gupta C; Chinnaswamy G; Qureshi S; Vora T; Khanna N; Laskar S
    Ann Diagn Pathol; 2018 Oct; 36():50-60. PubMed ID: 30098515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of PD-L1 expression in matched recurrent and/or metastatic sarcoma samples and in a range of selected sarcomas subtypes.
    Vargas AC; Maclean FM; Sioson L; Tran D; Bonar F; Mahar A; Cheah AL; Russell P; Grimison P; Richardson L; Gill AJ
    PLoS One; 2020; 15(4):e0222551. PubMed ID: 32294103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
    Chen D; Li G; Ji C; Lu Q; Qi Y; Tang C; Xiong J; Hu J; Yasar FBA; Zhang Y; Hoon DSB; Yao Y; Zhou L
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N).
    Ma J; Li J; Qian M; Han W; Tian M; Li Z; Wang Z; He S; Wu K
    Diagn Pathol; 2018 Nov; 13(1):91. PubMed ID: 30463584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort.
    Cocks M; Taheri D; Ball MW; Bezerra SM; Del Carmen Rodriguez M; Ricardo BFP; Bivalacqua TJ; Sharma RB; Meeker A; Chaux A; Burnett AL; Netto GJ
    Hum Pathol; 2017 Jan; 59():55-61. PubMed ID: 27663086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma.
    Pratt D; Dominah G; Lobel G; Obungu A; Lynes J; Sanchez V; Adamstein N; Wang X; Edwards NA; Wu T; Maric D; Giles AJ; Gilbert MR; Quezado M; Nduom EK
    Neurosurgery; 2019 Aug; 85(2):280-289. PubMed ID: 30011045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry.
    Shinchi Y; Komohara Y; Yonemitsu K; Sato K; Ohnishi K; Saito Y; Fujiwara Y; Mori T; Shiraishi K; Ikeda K; Suzuki M
    Cancer Sci; 2019 Sep; 110(9):2711-2721. PubMed ID: 31294893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and Prognostic Implications of PD-L1 Expression in Soft Tissue Sarcomas.
    Kelany M; Barth TF; Salem D; Shakweer MM
    Pathol Oncol Res; 2021; 27():1609804. PubMed ID: 34276259
    [No Abstract]   [Full Text] [Related]  

  • 31. Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression.
    Tretiakova M; Fulton R; Kocherginsky M; Long T; Ussakli C; Antic T; Gown A
    Mod Pathol; 2018 Apr; 31(4):623-632. PubMed ID: 29271413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes.
    Rosenbaum MW; Bledsoe JR; Morales-Oyarvide V; Huynh TG; Mino-Kenudson M
    Mod Pathol; 2016 Sep; 29(9):1104-12. PubMed ID: 27198569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer.
    Chen YL; Huang WC; Lin FM; Hsieh HB; Hsieh CH; Hsieh RK; Chen KW; Yen MH; Lee J; Su S; Marfatia T; Chang SE; Sundar P; Patterson B; Watson D; Mei R; Javey M
    Cancer Immunol Immunother; 2019 Jul; 68(7):1087-1094. PubMed ID: 31089757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas.
    Spurny C; Kailayangiri S; Jamitzky S; Altvater B; Wardelmann E; Dirksen U; Hardes J; Hartmann W; Rossig C
    Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28868758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.
    Xu SM; Shi CJ; Xia RH; Wang LZ; Tian Z; Ye WM; Liu L; Liu SL; Zhang CY; Hu YH; Zhou R; Han Y; Wang Y; Zhang ZY; Li J
    Front Immunol; 2021; 12():798424. PubMed ID: 35145511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
    Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
    Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer.
    Aydın EM; Demir TD; Seymen N; Said SS; Oktem-Okullu S; Tiftikci A; Cicek B; Tokat F; Tozun N; Ince U; Sezerman U; Sayi-Yazgan A
    Immunol Lett; 2021 Nov; 239():1-11. PubMed ID: 34363898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Programmed cell death ligand-1 (PD-L1) expression in extrahepatic biliary tract cancers: a comparative study using 22C3, SP263 and E1L3N anti-PD-L1 antibodies.
    Ahn S; Lee Y; Kim JW; Lee JC; Hwang JH; Yoon YS; Cho JY; Han HS; Choi Y; Kim H
    Histopathology; 2019 Oct; 75(4):526-536. PubMed ID: 31081949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of PD-L1 expression by immunohistochemistry and gene microarray with molecular subtypes of ovarian tumors.
    Chin CD; Fares CM; Campos M; Chen HW; Shintaku IP; Konecny GE; Rao J
    Mod Pathol; 2020 Oct; 33(10):2001-2010. PubMed ID: 32404957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.